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Abstract
Background: Whiplash injury affects 83% of persons in a traffic collision and leads to whiplash-associated disorders
(WAD). A major challenge facing health care decision makers is identifying cost-effective interventions due to lack
of economic evidence. Our objective is to compare the cost-effectiveness of: 1) physician-based education and
activation, 2) a rehabilitation program developed by Aviva Canada (a group of property and casualty insurance
providers), and 3) the legislated standard of care in the Canadian province of Ontario: the Pre-approved Framework
Guideline for Whiplash developed by the Financial Services Commission of Ontario.
Methods/Design: The economic evaluation will use participant-level data from the University Health Network
Whiplash Intervention Trial and will be conducted from the societal perspective over the trial’s one-year follow-up.
Resource use (costs) will include all health care goods and services, and benefits provided during the trial’s 1-year
follow-up. The primary health effect will be the quality-adjusted life year. We will identify the most cost-effective
intervention using the incremental cost-effectiveness ratio and incremental net-benefit. Confidence ellipses and
cost-effectiveness acceptability curves will represent uncertainty around these statistics, respectively. A budget
impact analysis will assess the total annual impact of replacing the current legislated standard of care with each of
the other interventions. An expected value of perfect information will determine the maximum research
expenditure Canadian society should be willing to pay for, and inform priority setting in, research of WAD
management.
Discussion: Results will provide health care decision makers with much needed economic evidence on common
interventions for acute whiplash management.
Trial Registration: http://ClinicalTrials.gov identifier NCT00546806 [Trial registry date: October 18, 2007; Date first
patient was randomized: February 27, 2008]
Keywords: budget impact analysis, cost-effectiveness analysis, expected value of perfect information, quality-
adjusted life year, whiplash-associated disorders, whiplash injury, treatment
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Whiplash injury affects 83% of persons involved in a
traffic collision [1]. In the short-term, this injury leads
to whiplash-associated disorder (WAD), a clinical syn-
drome characterized by neck pain and clusters of physi-
cal and psychological symptoms [2,3]. In the long-term,
whiplash injury increases the incidence of future health
problems. Persons with a history of whiplash are more
likely to suffer from future neck pain, headaches, low
back pain, shoulder pain and sleep disturbances, com-
pared to those without a history of whiplash [1,4-6].
WAD represents an important and growing burden
both in terms of direct medical costs (associated with
health care use) and indirect costs (associated with pro-
ductivity changes, lost earnings capacity, and time con-
tributed by caregivers) [7]. Most industrialized countries
have seen a rise in the incidence of hospital visits for
traffic-related WAD over the past 20 years [8]. In the
Netherlands, the average annual incidence has increased
10 times over a twenty-year period, from 3.4 visits per
100,000 inhabitants (1970-1974) to 40.2 visits per
100,000 (1990-1994) [9]. In Sweden, the annual cumula-
tive incidence of emergency visits for WAD has
increased from 83 per 100,000 inhabitants (1985-1986)
to 302 per 100,000 (1997-1998) [8].
In the Canadian province of Ontario, health care
resources used to manage traffic injuries within the
automobile insurance system exceed those used by the
Workers Safety and Insurance Board system for similar
injuries [10]. A recent assessment of sprain and strain
(mainly whiplash) injuries from 2004 - 2007 by the
Ontario insurance industry found that despite a 20%
increase in costs over the 3-year time period, the per-
cent of claims closed within the expected time frame for
soft tissue injuries declined dramatically [10]. Thus
WAD claims have increased in duration, despite the fact
that more health care resources have been directed to
WAD management. Drivers in Ontario consequently
pay much higher automobile insurance premiums com-
pared to drivers in other Canadian provinces where
automobile insurance is also sold by private companie
[11]. About, 5% of Ontario motorists’ disposable income
is spent on auto insurance, whereas motorists in Alberta
and the Atlantic provinces pay 3% [10]. Recent scientific
studies have also observed that increasing health care
use has not led to improved health outcomes in WAD
patients. Two population-based studies in Saskatchewan
found that higher health care use was associated with
substantial delays in recovery that were not explained by
injury severity or other factors [12,13]. Another study
found that when compared to usual care, specialized
rehabilitation programs did not benefit recovery from
WAD [14]. A 2006 randomized trial compared educa-
tion and advice by general practitioners (mean number
of visits = 3.0) to education and exercises by phy-
siotherapists (mean number of visits = 12.7) in patients
with WAD lasting more than four weeks [15]. Patients
in the general practitioner group reported lower levels
of neck pain and headache intensity than patients trea-
ted by physiotherapists [15].
Thus, a major challenge facing health care decision
makers is identifying cost-effective interventions for
WAD. But there are no economic evaluations of WAD
interventions in the published literature. The recently
published systematic review of the neck pain literature
by the Bone and Joint Decade 2000-2010 Task Force on
Neck Pain and Its Associated Disorders did not identify
a single cost-effectiveness analysis of WAD treatments
[16]. Our objective is to conduct an economic evalua-
tion alongside a pragmatic randomized trial that evalu-
ates physician-based education and activation and two
rehabilitation programs for managing WAD in real-
world conditions.
Methods/Design
This paper describes the protocol of an economic eva-
luation alongside the University Health Network
Whiplash Intervention Trial (UHN WIT). A complete
description of the UHN WIT protocol has
been published elsewher [17]. and is summarized
below.
University Health Network Whiplash Intervention Trial
Protocol
The UHN WIT is a three-arm randomized trial
designed to compare the effectiveness of education and
activation by a physician and two rehabilitation pro-
grams of care in patients with recent Grade I or II
WAD (Table 1). Selection criteria are listed in Table 2
and the interventions are summarized below [17]. The
UHN WIT protocol was approved by the University
Health Network Research Ethics Board (January 4,
2008).
Table 1 The Québec Classification of Whiplash-associated
Disorder [2].
Grade Clinical Presentation
0 No neck symptoms, no physical sign(s)
I Neck pain, stiffness or tenderness only, no physical sign(s)
II Neck symptoms and musculoskeletal sign(s)*
III Neck symptoms and neurologic sign(s)†
IV Neck symptoms and fracture or dislocation
*Musculoskeletal signs include decreased range of motion and point
tenderness.
†Neurologic signs include decreased or absence of deep tendon reflexes,
weakness, and sensory deficits.
Symptoms and disorders that can be manifested in all grades include
deafness, dizziness, tinnitus, headache, memory loss, dysphagia, and
temporomandibular pain.
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The Education and Activation intervention is designed
to promote self-efficacy and early return to normal
activities of daily living. It reflects current guidelines and
recommendations for the management of WAD [18,19].
A primary care physician provides reassurance, educa-
tion about WAD’s favorable prognosis, encouragement
to resume activities of daily living, and a recommenda-
tion to perform home stretching exercises. The physi-
cian prescribes medicinal or non-medicinal pain relief
modalities (heat/ice), a physiotherapy visit for further
instruction on home exercises, or both, based on clinical
judgment. The physician determines whether the partici-
pant can be discharged or a follow-up visit is required at
the end of the first visit. The participant is advised to
contact the physician if the complaint persists or
worsens.
If follow-up visits are required, the participant is re-
assessed by the same physician (if the physician is una-
vailable, another physician associated with the trial re-
assesses the participant). The intervention above is
repeated and adapted to the participant’s status accord-
ing to the physician’s clinical judgment (e.g., alternate
pain medication is prescribed). Participants who do not
recover six weeks post-collision, or improve but require
more care, are referred for a multidisciplinary evaluation
and enter the interdisciplinary rehabilitation intervention
stream (described in the Soft Tissue Injury Care Model
section below).
Pre-approved Framework Guideline for Grade I and II
Whiplash-associated Disorders
The Pre-approved Framework is a clinical management
guideline developed by the Financial Services
Commission of Ontario, an arm’s length agency of the
Ministry of Finance which regulates traffic insurance in
the province of Ontario. It is the legislated standard of
care for Grade I and II WAD in Ontario. It focuses on
the provision of interventions to manage pain and dis-
ability through functional restoration [20]. The interven-
tion is administered by a physiotherapist and includes:
1) reassurance, 2) education, 3) home exercises, and 4)
encouragement to resume normal activities of daily liv-
ing. The physiotherapist may also provide: 1) exercise
and functional activities, 2) mobilization and manipula-
tion, 3) non-medicinal pain management modalities
(heat/ice, massage therapy), and 4) coping skills educa-
tion. The frequency and number of visits is based on
the physiotherapist’s clinical judgment, but does not
exceed 10 visits within the first three weeks and 9 visits
three to six weeks after the collision date. The limit on
the number of visits is a restriction of the Pre-approved
Framework, not of the trial protocol.
Participants with clinically important functional limita-
tions are eligible for a functional assessment of their
home, work, or school environment. Based on the
assessment, an occupational therapist develops an inter-
vention that may include: 1) recommendation to use
aids or devices, 2) minor modifications at the work,
home, or school environment, 3) instructions on adap-
tive strategies or alternate approaches to fulfill func-
tional tasks, and 4) specific functional activities to
increase tolerance. Participants who report clinically sig-
nificant improvement in the first six weeks of care, but
have not recovered, can receive up to four additional
treatments over a two-week period. Participants who
have not recovered in the first six weeks of care are re-
Table 2 Selection criteria for the University Health Network Whiplash Intervention Trial [17]
Inclusion criteria
18 years of age or older.
Reside or work in the Greater Toronto Area, Mississauga, Burlington, Cambridge, Kitchener, Ajax, Pickering, or the Durham region in the province of
Ontario, Canada.
Make an insurance claim for physical injury to Aviva Canada* between February 1, 2008 to March 31, 2012 within 21 days of the traffic collision.
Report an average neck pain since the accident of at least 3 on a 0-10 numerical rating scale.
Are injured in a motor vehicle collision with clinician-assessed Grade I or II WAD.
Are able to provide written informed consent and complete interviews in English (translators will be available to assist the participant if the claimant
experiences difficulty understanding specific items on the questionnaire).
Exclusion criteria
Fracture/dislocation of the spine or any major bone.
Head trauma associated with loss of consciousness.
Past whiplash or work-related neck injury within the year prior to current WAD injury.
Active systemic diseases (cancer, inflammatory arthritis, disorders of central nervous system).
Previous neck surgery.
Received treatment from a physiotherapist or chiropractor for neck pain in the three months preceding the motor vehicle collision.
Does not reside or work in Greater Toronto Area, Mississauga, Burlington, Cambridge, Kitchener, Ajax, Pickering, or the Durham region in the
province of Ontario, Canada.
WAD = Whiplash-associated Disorder (See Table 1 for definition of Whiplash-associated Disorder grading system).
*Aviva Canada is a group of property and casualty insurance providers.
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by the physiotherapist.
Soft Tissue Injury Care Model
The Soft Tissue Injury Care Model is a staged multidis-
ciplinary rehabilitation program developed by Aviva
Canada (a group of property and casualty insurance pro-
viders) as an alternative to the Pre-approved Framework
guideline. A physiotherapist leads the intervention
which includes three integrated and sequentially-admi-
nistered rehabilitation phases: 1) acute-sub acute care,
2) multidisciplinary evaluation, and 3) interdisciplinary
rehabilitation. During the acute-sub acute phase (first
six weeks post-collision), care is delivered by phy-
siotherapists, and if necessary, kinesiologists and mas-
sage therapists. Care consists of: 1) reassurance, 2)
education, 3) home exercises, 4) physiotherapy modal-
ities, and 5) massage therapy. A maximum of 9 treat-
ments (including massage therapy) during the first three
weeks post-collision and an additional 8 sessions
(including massage therapy) between the third and sixth
week post-collision is provided. The limit on the num-
ber of visits is a restriction of the Soft Tissue Injury
Care Model, not of the trial protocol. The type and fre-
quency of treatment prescribed by the physiotherapist is
based on his/her assessment. During this phase, the phy-
siotherapist may recommend an in-home or job-site
functional assessment.
Patients who require treatment beyond the acute-sub
acute phase are referred for a multidisciplinary evalua-
tion. The purpose of the multidisciplinary evaluation is
to identify barriers to recovery and recommend the
appropriate treatment through an interdisciplinary reha-
bilitation program. The interdisciplinary rehabilitation
program has three specific goals: 1) overcome psychoso-
cial barriers to return to function, 2) physical restora-
tion, and 3) functional restoration. The program
includes up to five weeks of daily intervention (each ses-
sion may last up to 51/2 hours). Frequency, duration
and type of care are determined by the interdisciplinary
team and may include a job-site assessment. Services
provided during interdisciplinary rehabilitation may
include: 1) education, 2) reassurance, 3) goal setting and
advice on self-management, 4) psychological counseling
and stress management, 5) relaxation therapy, psy-
chotherapy and family counseling, 6) cognitive beha-
vioral therapy, 7) instruction on pain management
techniques, and 8) strength, endurance, flexibility or car-
diovascular exercises.
Quality Control
All physicians and physiotherapists are trained by a trial
coordinator during a formal training session. The ses-
sion consists of a description of the study and instruc-
tion on the standardized intervention protocols.
Clinicians receive printed materials to refer to. A trial
coordinator conducts intermittent file audits and proto-
col reviews with clinicians to ensure adherence with the
protocol.
Data Collection, Follow-up, and Outcomes
Table 3 summarizes data collected during the trial. Par-
ticipants are assessed at 6 weeks, and 3, 6, 9 and 12
months from baseline. The UHN WIT primary outcome
is time-to-recovery measured by a global self-perceived
recovery question - a reliable, valid, and responsive mea-
sure of health status in patients with musculoskeletal
disorders [21,22]. Participants are asked: “How well do
you feel you are recovering from your injuries?” at each
follow-up. They are requested to select one of seven
choices: 1) completely better; 2) much improved, 3)
slightly improved, 4) no change, 5) slightly worse, 6)
much worse, and 7) worse than ever. Participants who
respond to have “completely recovered” or are “much
improved” are considered to have recovered. Time-to-
recovery is measured as number of days between the
date of injury and the first follow-up date that a partici-
pant reports to be “completely recovered” or “much
improved”.
Secondary outcomes include the following. A recur-
rence occurs when a participant who reports to have
recovered subsequently reports that s/he is: 1) slightly
worse, 2) much worse, or 3) worse than ever. Neck pain
intensity is measured with an 11-point numerical rating
s c a l e[ 2 3 ] .T h en u m e r i c a lr a t i n gs c a l ei sam e a s u r eo f
pain intensity anchored by two extremes of pain inten-
sity varying from 0 (no pain) to 10 (pain as bad as it
could be). Disability is measured with the Whiplash Dis-
ability Questionnaire [24]. The questionnaire includes
13 Likert scales scored from 0 to 10 with higher global
scores indicating more disability. The acute 36-item
Medical Outcomes Study Short-Form Health Survey
(version 2) is used to measure health-related quality-of-
life [25-27]. Depressive symptoms are measured with
the Center for Epidemiological Studies-Depression Scale
[3,28,29]. The scale is scored from 0 to 60 with higher
scores indicating greater depressive symptomatology
[30,31]. Co-interventions are measured by asking partici-
pants to self-report the type of health care provider con-
sulted outside of the trial and the frequency of these
visits. Participants are also asked to self-report medica-
tion use, including over-the-counter medication and
drugs prescribed by heath providers not associated with
the trial. A cross-validation will be conducted by check-
ing self-reported co-interventions against the out-of-
pocket expenses submitted by participants to Aviva
Canada for reimbursement. (See ‘Resource Use (Costs)’
section below for more information on out-of-pocket
expenses paid by the automobile insurer).
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The primary analysis will be conducted according to the
intention-to-treat principle. It will compare time-to-
recovery across intervention arms using the Kaplan-
Meier method, reporting median time-to-recovery and
95% confidence intervals [32]. The mixed-effect Cox
proportional hazards model will be used to measure the
relative effectiveness of Education and Activation, Pre-
approved Framework, and Soft Tissue Injury Care
Model [33-36]. If participant baseline characteristics
vary between interventions, a multivariable mixed-effect
Cox proportional hazards model will be used to control
for differences between groups. The proportional
hazards assumption of a constant hazard ratio will be
tested using graphical approaches, goodness-of-fit tests,
and time-dependent variables. A stratified Cox proce-
dure will be used if the assumption does not hold [37].
Recurrences will be reported as rates (number of par-
ticipants that report a recurrence per 28 days). Rates
will be used because differences in participants’ time-to-
recovery could create a bias that favors less effective
interventions (those with longer average time-to-recov-
ery) since, in participants randomized to these interven-
tions, there will be less observation time to observe
potential recurrences. Time-to-recurrences will also be
compared in a Cox proportional hazards model as
above, with an additional covariate to account for differ-
ences in average time-to-recovery across interventions.
Economic Evaluation alongside the UHN WIT
The primary objective is to compare the relative cost-
effectiveness of: 1) the legislated standard of care in
Ontario for acute WAD, 2) physician-based Education
and Activation, and 3) the Soft Tissue Injury Care Pro-
gram, for persons with recent WAD injury, using parti-
cipant-level data from the UHN WIT and Aviva Canada
administrative claim files. Secondary objectives including
conducting sensitivity analyses, an expected value of
perfect information analysis, and a budget impact analy-
sis. A societal perspective will be adopte [38,39]. The
time horizon will be 12 months (the maximum follow-
up for the trial).
Resource Use (Costs)
Ontario automobile insurance regulations specify that
extended health care benefits (e.g., benefits provided by
employers on top of public health care benefits) are
used first when paying for traffic injury treatment.
When extended benefits are exhausted, automobile ben-
efits are used. However in this trial, Aviva Canada pays
for all health care, including those generally paid by
extended care benefits.
Relevant costs will include all health care goods and
services, and benefits provided by Aviva Canada during
the study’s 12-month follow-up period (Table 4). Partici-
pants will not be requested to complete cost diaries
since patient out-of-pocket expenses are paid by auto-
mobile insurance providers in Ontario. Therefore,
expenses submitted by participants to Aviva Canada will
be used as a proxy to a cost diary. At all follow-ups,
participants also complete a questionnaire about access
to health care for their whiplash injury beyond health
care provided by the trial (i.e., publicly or privately
funded or unfunded health provider services). Costs will
Table 3 Outcomes and variables measured at baseline and follow-up interviews
Measures Baseline 6
Weeks
3 Months 6
Months
9 Months 12
Months
Socio-demographic characteristics x
Accident information x
Past history of neck pain and whiplash x
Health care after accident x
Co-morbidity questionnaire x
Neck pain intensity x x x x x X
Whiplash disability questionnaire x x x x x X
SF-36 (acute, v2) x x xxxx
CES - Depression scale x x xxxx
Health state preference (rating scale) x x xxxx
Expectation of recovery x x xxxx
Global self-perceived recovery question x x xxxx
Work status x x xxxx
Lawyer or paralegal involvement x x xxxx
Satisfaction with care x xxxx
Co-interventions x xxxx
CES = Center of Epidemiological Studies; SF-36 (acute, v2) = Medical Outcomes Study 36-item Short-Form health survey (acute, v2)
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Ministry of Health and Long-term Care Schedule of
Benefits (for physician visits, which are publicly funded)
or 2) regulated health professions’ recommended fee
schedules (for acupuncture, chiropractic, massage ther-
apy, naturopathy, physiotherapy visits, etc., which are
not publicly funded). Unit values for over-the-counter
and prescription drugs will be obtained from a whole-
sale distributor catalogue.
Cost data will be extracted from participants’ insur-
ance claim file by a blinded research associate unaffi-
liated with Aviva Canada using a standard data
extraction form. The research associate will pilot data
extraction by extracting data twice from the files of the
first 50 participants to test intra-rater reliability. A value
of at least 0.8 will be considered adequate for the quad-
ratic weighted Kappa statistic (in the case of categorical
data) and intra-class correlation coefficient (in the case
of continuous data). Data extraction will be modified if
problems are identified. Cost data will be linked with
trial data using the unique study identification number
assigned to each participant at enrollment. Costs will be
reported in Canadian dollars and standardized for infla-
tion to the most recent available rates after the study
has ended, using the Bank of Canada Consumer Price
Index and adjusted for censoring using the Kaplan-
Meier sample average estimator [40-42].
Health Effects (Outcomes)
We will use the quality-adjusted life year (QALY) as the
primary health outcome for our analysis. SF-6D scores -
derived from SF-36 response data - will be used to esti-
mate participants’ preference-based quality-of-life (utili-
ties) over the 12-month follow-up period [43]. These
scores will be converted into a within-trial estimate of
participant-level QALYs using the area-under-the-curve
approach, with linear interpolation between assessment
points and adjusting for potential differences in baseline
characteristics [44]. The number of unrecovered days
will be derived from the trial’sp r i m a r yo u t c o m e‘time-
to-recovery’ based on participants’ self-perceived recov-
ery. Mean number of unrecovered days will be adjusted
for censoring using the Kaplan-Meier product limit esti-
mator [32,37]. The number of recurrences will be
derived from the trial’s secondary outcome, standardized
to a rate (number of recurrences per 28 days) to
account for differences in participants’ time-to-recovery.
Statistical Analysis
Participant characteristics and health resources con-
sumed will be reported by intervention group, using
descriptive statistics (measures of central tendency and
variance).
Primary Cost-effectiveness Analysis
Costs and health effects will not be discounted for the
primary analysis since the time horizon is 12-months.
Following current recommendations [38]. costs related
to productivity changes (e.g., income replacement,
excess economic loss benefits) will not be included in
the primary cost-effectiveness analysis. Productivity
changes will be reported separately, including quantities
(e.g., days of work lost) and prices used to value the
quantities. We will calculate mean cost per patient and
mean effect per patient by intervention group, based on
initial intervention assignment, with costs and effects
adjusted for censoring [41]. We will identify the cost-
Table 4 Resource use (costs) to be collected
Costs Examples
Health care provider fees Initial assessment, follow-up visits.
Fees for completing standardized
automobile insurance claims
forms
Treatment Plan (OCF-18), Discharge
and Status Report (OCF-24).
Health services (block fees) In-home assessment, functional
evaluation, job site assessment,
home exercise prescription,
multidisciplinary evaluation,
workplace/home modification
assessment, home exercise
prescription, multidisciplinary
evaluation, workplace/home/vehicle
modification assessment, return to
work support, education programs,
life skills and job retraining,
counseling and coaching, stress
management, relaxation therapy,
family counseling, cognitive
behavioral therapy, pain
management.
Patient out-of-pocket expenses Over-the-counter medications,
prescription drugs, portable
electrotherapy devices, orthotics,
assistive devices, health care
supplies, treatment-related
expenses.
Diagnostic imaging Radiography, magnetic resonance
imaging, ultrasound.
Benefits Non-earner, dependent care,
caregiver, housekeeping and home
maintenance, income replacement,
attendant care, lost educational
expenses, expense of visitors, long-
term care, excess economic loss.
Independent health examination Chiropractic, medical, occupational
therapy, physical therapy,
psychological.
OCF = Ontario Claim Form
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cost-effectiveness ratio and incremental net-benefit.
Confidence ellipses (50%, 75%, 95%) and cost-effective-
ness acceptability curves will represent the uncertainty
around these statistics, respectively.
Incremental cost-effectiveness will be computed as the
ratio of the difference in mean costs (incremental cost,
ΔC) to the difference in mean health effects (incremen-
tal effect, ΔE), and will provide incremental cost-effec-
tiveness ratios (ICERs):
ICER =  C/ E
ICERs will represent the additional cost per additional
QALY gained, additional cost per additional unrecov-
ered day averted, and additional cost per additional
recurrence over a 28 day period of one intervention
compared to another, from least costly to most costly.
ICERs will be plotted on a cost-effectiveness plan
[45,46]. with uncertainty represented by confidence
ellipses [47-49]. which are a two-dimensional generaliza-
tion of the confidence interval. We will estimate the dis-
tribution of mean incremental costs and effects by the
non-parametric re-sampling technique of bootstrapping
with replacement from 10,000 replicates and presented
as a scatter plot on the cost-effectiveness plane [48,49].
Whether the ICER is considered cost-effective by a
decision maker depends on the maximum the decision
maker is willing to pay for an extra unit of health effect
(the threshold value, l). An intervention that is cost-
effective is thus defined as ICER < l. The Incremental
Net Benefit (INB) equatio [50]. computes the net benefit
of a health effect in dollars, by valuing the additional
health effect (ΔE) in dollars, and subtracting the asso-
ciated additional cost (ΔC) as follows:
INB = ( E × λ) −  C
When the INB is positive, the value of a new treat-
ment’s extra benefits (ΔE×l) outweighs its extra costs
(ΔC), implying that the decision maker values the extra
effect more than the extra cost (i.e., ΔE×l > ΔC). Con-
versely, when INB is negative, the decision maker does
not consider the extra benefit to be worth the extra cost.
We will use the net-benefit approac [50,51]. to mea-
sure the incremental cost-effectiveness of the interven-
tions against a threshold value l,w h e r el will be
described as society’s maximum willingness-to-pay for
an additional: 1) QALY gained, 2) unrecovered day
averted, and 3) recurrence averted over a 28 day period.
We will compute INB over a range of willingness-to-pay
threshold values based on $50,000 per QALY and other
values cited in the health economics literature. Uncer-
tainty will be represented by cost-effectiveness accept-
ability curves [47,52,53]. Cost-effectiveness acceptability
curves are derived from the joint density of incremental
costs and incremental effects for an intervention of
interest and represent the proportion of the density
where an intervention is cost-effective for a range of l
values [54]. In this study, the joint density will be
obtained by non-parametric bootstrapping from the dis-
tribution of observed cost-effect pairs. Cost-effectiveness
acceptability curves will show the probability that the
interventions are cost-effective over a full range of
values for l for an additional unit of health effect.
We will examine baseline characteristics across inter-
vention groups to determine whether randomization
was successful in balancing observed baseline covariates.
If there is unbalanced allocation in baseline characteris-
tics, we will use net-benefit regression [55] which allows
cost-effectiveness to be estimated directly in a regression
framework. Net-benefit regression uses net-benefit as
the dependent variable calculated from person-level
effect (Ei) and cost (Ci) data for each patient i:
NBi =( E ixλ) − Ci
In its simplest form, regression is then used to esti-
mate:
NBi = α + βti + εi
where a is the intercept term, t is an intervention
dummy term (it equals 1 if the person received, for
example, the new intervention and 0 for the usual care),
and ε is the stochastic error term. The regression coeffi-
cient b provides the estimate of the standard incremen-
tal net-benefit statistic. As there are two new
interventions to test, we will use two treatment dum-
mies, t1 and t2 (with corresponding coefficients b1 and
b2). The regression estimate of b1 will equal the incre-
mental net benefit of physician-based Education and
Activation compared to the Ontario legislated standard
of care, and the regression estimate of b2 will equal the
incremental net benefit of the Soft Tissue Injury Care
Program compared to the Ontario legislated standard of
care. Additional covariates can be added to adjust for
unbalanced allocation in observed baseline covariates
that could confound results [55]. Subgroups for whom
new interventions are especially cost-effective can be
identified through interaction terms (e.g., X*t).
Sensitivity Analyses
Sensitivity analyses will test the robustness of results to
selected issues and assumptions. First, cost-effectiveness
will be re-evaluated with costs related to productivity
changes included as these costs will not be included in
the primary analysis. Second, the sensitivity of the
results to using SF-6D versus rating scale quality-of-life
weights to calculate QALYs will be tested. The rating
scale approach consists of asking participants to choose
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on a scale anchored from 0 (worst imaginable health
state) to 100 (best imaginable health state) [56]. Finally,
we will test assumptions about the long-term costs and
effect of the interventions extrapolated beyond the 12-
month time horizon, including the assumptions that: 1)
after the 12-month period, the rate of recovery is identi-
cal, and 2) the interventions continue to confer the
same rate of recovery. These assumptions will be extra-
polated over a 5-year time horizon [57].
Missing Data and Loss to Follow-up
Observations with incomplete baseline covariates will be
deleted from the analyses. Participants with missing data
on the primary outcome (self-perceived recovery) and
preference-based quality-of-life (SF-6D) will have the
result of their last observation carried forward. Sensitiv-
ity analyses will be conducted, where reasonably likely
scenarios are considered (e.g., missing observations are
assumed to have a distribution of outcomes including
recovery, recurrence, and no recovery). Cost and effect
data will be analyzed with two approaches: 1) only parti-
cipants with complete data are included (complete case
analysis), and 2) all study participants are included,
where imputed values for costs and effects in partici-
pants with missing data will be used (multiple imputa-
tion) [58]. Results of the multiple imputation analysis
will be compared to the complete case analysis [59,60].
Expected Value of Perfect Information
Expected value of perfect information (EVPI) represents
the maximum amount that a health care decision maker
should be willing to pay for additional evidence to
inform future decisions [38]. It focuses on the value of
obtaining further information to reduce uncertainty. We
will estimate EVPI per participant, multiply this value by
the average annual number of WAD claims in Ontario
over a previous five year period, and plot this resultant
population EVPI for a range of willingness-to-pay
thresholds. The results will provide the maximum
expenditure that society or a health care decision maker
should be willing to pay for, and inform priority setting
in, WAD management research.
Budget Impact Analysis
A budget impact analysis will be conducted to assess the
cost of replacing the Pre-approved Framework Guideline
(the current legislated standard of care for acute Grade I
and II WAD in Ontario) with the physician-based Edu-
cation and Activation and Aviva Canada’s Soft Tissue
Injury Care Model [61,62]. The total annual impact on
the budget of the automobile insurer and subsequent
implication to automobile premiums in Ontario will be
considered using published underwriting ratios (an
underwriting - or combined - ratio is a measure of an
insurance company’s profitability). Analytic assumptions
will be based on published epidemiological WAD inci-
dence rates, automobile insurance traffic injury rates,
and data collected by this economic evaluation [1,10].
Conclusion
This paper allows for the peer-review of the proposed
methods and provides a transparent statement of the
planned analyses. Results of this economic evaluation
are expected to provide health care decision makers
with necessary economic evidence on common interven-
tions for acute whiplash.
List of abbreviations
EVPI: expected value of perfect information; ICER: incremental cost-
effectiveness ratio; INB: incremental net-benefit; QALY: quality-adjusted life
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